Back to Search
ANTONY RAUBITSCHEK, MD, PHD
MD, PHD
Hospitalist Physician
NPI: 1770900862IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
MD60681544(WA)
Hospitalist PhysicianPrimary
Hospitalist
Code: 208M00000X
MD60681544(WA)
Education
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Class of 2014
Research & Publications (20)
A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.
PMID 19351765·Clin Cancer Res·2009
3-trial
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
PMID 19549776·Clin Cancer Res·2009
4-observational
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
PMID 18509084·Blood·2008
3-trial
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
PMID 18025438·J Clin Oncol·2008
3-trial
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.
PMID 18771344·Cancer Biother Radiopharm·2008
7-preclinical
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
PMID 18453625·J Immunol·2008
8-other
Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.
PMID 18312824·Nucl Med Biol·2008
7-preclinical
Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.
PMID 18720981·Bioconjug Chem·2008
7-preclinical
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
PMID 18559603·Clin Cancer Res·2008
7-preclinical
A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.
PMID 17988078·Bioconjug Chem·2008
7-preclinical
Intratumoral immunocytokine treatment results in enhanced antitumor effects.
PMID 18438664·Cancer Immunol Immunother·2008
7-preclinical
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
PMID 17363611·Cancer Res·2007
7-preclinical
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
PMID 17685852·Hum Gene Ther·2007
8-other
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
PMID 17234783·Cancer Res·2007
4-observational
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
PMID 16706629·Cancer Biother Radiopharm·2006
3-trial
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
PMID 16877732·J Clin Oncol·2006
3-trial
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
PMID 15994969·Cancer Res·2005
7-preclinical
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
PMID 16002426·Blood·2005
3-trial
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
PMID 16034043·J Clin Oncol·2005
7-preclinical
T-cell genetic modification for re-directed tumor recognition.
PMID 16110618·Cancer Chemother Biol Response Modif·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1550 N 115TH ST
SEATTLE, WA 98133 - Phone
- (206) 520-5000
Quick Facts
- NPI
- 1770900862
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile